IMTX
NASDAQImmatics N.V.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks54+100%
2026-03-012026-08-23
Mix2290d
- Insider11(50%)
- Other5(23%)
- SEC Filings5(23%)
- Offering1(5%)
Latest news
25 items- PRImmatics Announces $150 Million Underwritten OfferingHouston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, announced today that it has agreed to sell 12,945,916 ordinary shares at $8.69 per share and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 4,315,304 ordinary shares at a purchase price of $8.689 per pre-funded warrant, which represents the per share offering price less the $0.001 per share exercise price for each pre-funded warrant, in an underwritten offering. The gross proceeds from the offering, before deducting
- INSIDERSEC Form 4 filed by Gen Counsel and Corp Secretary Pepin James Nelson4 - Immatics N.V. (0001809196) (Issuer)
- SECSEC Form 6-K filed by Immatics N.V.6-K - Immatics N.V. (0001809196) (Filer)
- PRImmatics Announces Second Quarter 2026 Financial Results and Business UpdateEnrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) remains on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint; aggregate PFS events (progression or death) occurring more slowly than originally modeledCompany plans to proceed directly to a streamlined final analysis for the primary endpoint, PFS, while strengthening power for the secondary endpoint, OS, to enhance the commercial product profile SUPRAME topline data disclosure for the final PFS analysis expected in H1 2027, followed by BLA submission in 2027Anzu-cel PRAME Cell Therapy: Updated Phase 1b data at ASCO 2026 continued to show durable
- INSIDERSEC Form 3 filed by new insider Pepin James Nelson3 - Immatics N.V. (0001809196) (Issuer)
- PRImmatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026Houston, Texas and Tuebingen, Germany, July 17, 2026 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced three presentations at the European Society for Medical Oncology (ESMO) Congress 2026, to be held from October 23-27, 2026, in Madrid, Spain. The three presentations will include: Phase 1b data from anzu-cel, the Company’s lead PRAME cell therapy, in metastatic cutaneous and uveal melanoma, focusing on predictors of durable responsePhase 1 data from IMA203CD8 PRAME cell therapy across multiple PRAME-positive solid tumors, including du
- SECSEC Form S-8 filed by Immatics N.V.S-8 - Immatics N.V. (0001809196) (Filer)
- INSIDERSEC Form 4 filed by Director Stone Adam Leo4 - Immatics N.V. (0001809196) (Issuer)
- INSIDERSEC Form 4 filed by Director Reicin Alise4 - Immatics N.V. (0001809196) (Issuer)
- INSIDERSEC Form 4 filed by Director Atieh Michael G4 - Immatics N.V. (0001809196) (Issuer)
- INSIDERSEC Form 4 filed by Director Carter Paul Rutherford4 - Immatics N.V. (0001809196) (Issuer)
- INSIDERSEC Form 4 filed by Director Forster Eliot4 - Immatics N.V. (0001809196) (Issuer)
- INSIDERSEC Form 4 filed by Director Chambre Peter Alan4 - Immatics N.V. (0001809196) (Issuer)
- INSIDERSEC Form 4 filed by Director Perceptive Advisors Llc4 - Immatics N.V. (0001809196) (Issuer)
- INSIDERSEC Form 4 filed by Director Mason Heather L4 - Immatics N.V. (0001809196) (Issuer)
- INSIDERSEC Form 4 filed by Director Hothum Mathias4 - Immatics N.V. (0001809196) (Issuer)
- SECSEC Form 6-K filed by Immatics N.V.6-K - Immatics N.V. (0001809196) (Filer)
- SECSEC Form 6-K filed by Immatics N.V.6-K - Immatics N.V. (0001809196) (Filer)
- SECSEC Form 6-K filed by Immatics N.V.6-K - Immatics N.V. (0001809196) (Filer)
- PRImmatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual MeetingOne-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and metastatic uveal melanomaAnzu-cel showed a 56% confirmed ORR, 14.6 months mDOR, 6.1 months mPFS and 16.2 months mOS at longer follow-up alongside a predictable and manageable tolerability profile in metastatic melanoma Exploratory response analysis suggests continued control of baseline disease and anti-tumor activity across multiple metastatic disease sites with many lesions remaining controlled, some even after progressionFindings reinforce the continued effectiveness of anzu-cel to treat advanced
- PRImmatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung CancerIMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancerIn head and neck cancer, IMA401 treatment at recommended Phase 2 dose (RP2D) with or without pembrolizumab resulted in a 29% confirmed ORR (4/14), 64% DCR (9/14) and mDOR of 8.8 months; all responders achieved deep responses with 60-100% tumor reduction IMA401 MAGEA4/8 TCR bispecific demonstrated favorable tolerability at RP2D with or without pembrolizumab, suggesting its potential for broad combinability IMA401 data will be presented in an oral presentation at the 2026 ASCO Annual Meeting and published simultaneously
- PRImmatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual MeetingOne-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer with a 63% objective response rate (ORR), 50% confirmed ORR (cORR), including four complete responses, and longest ongoing response at 12 monthsAdditional Phase 1 data for IMA203CD8 in heavily pretreated patients with synovial sarcoma showed deep and durable responses with a 67% ORR and 64% cORR, including one complete response, and ongoing responses up to ~3 yearsIMA203CD8 demonstrated a manageable and consistent tolerability profile across patient populationsClinical anti-tumor activity observed
- SECSEC Form SCHEDULE 13G filed by Immatics N.V.SCHEDULE 13G - Immatics N.V. (0001809196) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Immatics N.V.SCHEDULE 13G/A - Immatics N.V. (0001809196) (Subject)
- SECSEC Form 6-K filed by Immatics N.V.6-K - Immatics N.V. (0001809196) (Filer)
IMTX FAQ
6 questionsWhat does Immatics N.V. do?
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets...Where does IMTX stock trade?
Immatics N.V. (IMTX) is listed on NASDAQ.What sector and industry is IMTX in?
Immatics N.V. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about IMTX?
Immatics N.V. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy on 2026-04-28. Recent price targets range from $1000.00 to $1900.00.What companies are similar to IMTX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare IMTX side-by-side with any of them on Quantisnow.How can I track IMTX on Quantisnow?
Quantisnow aggregates Immatics N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMTX to receive live email and push alerts on every new disclosure.